Related Experiment Video
Updated: Mar 21, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.7K
Phosphodiesterase 4 Inhibitor Use in Pediatric Patients With Atopic Dermatitis: A Meta-Analysis of Randomized
Gui-Lin Ran1, Li-Chin Lu2, Hui-Bin Wang3
1The People's Hospital of Tongliang District, Chongqing.
Advances in Skin & Wound Care
|March 20, 2026
Summary
Topical phosphodiesterase 4 (PDE4) inhibitors show significant efficacy in treating pediatric atopic dermatitis (AD), improving clinical scores without increasing adverse events. This meta-analysis confirms their potential as a safe treatment option for children with AD.
Area of Science:
- Dermatology
- Pharmacology
- Pediatrics
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting pediatric populations.
- Topical phosphodiesterase 4 (PDE4) inhibitors represent a targeted therapeutic approach for AD.
- Evaluating the efficacy and safety of these agents in children is crucial for clinical practice.
Purpose of the Study:
- To conduct a meta-analysis comparing the clinical efficacy and safety of topical PDE4 inhibitors versus vehicle control in pediatric patients with atopic dermatitis.
- To synthesize data from randomized controlled trials (RCTs) to provide robust evidence on treatment outcomes.
Main Methods:
- Systematic literature search of major databases (PubMed, Cochrane, EBSCO, Web of Science, Ovid) up to September 2023.
- Inclusion of five RCTs involving 1877 pediatric patients with mild-to-moderate AD, comparing topical PDE4 inhibitors with vehicle control.
- Meta-analysis performed using random-effects models according to PRISMA guidelines.
Main Results:
- Topical PDE4 inhibitors significantly improved Investigator Global Assessment scores (OR: 3.56) and treatment success rates at weeks 2 and 4 (ORs: 4.09, 3.06).
- Significant reductions in Eczema Area and Severity Index (EASI) scores were observed (OR: -4.11).
- No statistically significant differences were found in overall adverse events (OR: 1.16) or drug-related adverse events (OR: 1.46) compared to vehicle control.
Conclusions:
- Topical PDE4 inhibitors demonstrate significant clinical efficacy in improving AD symptoms in pediatric patients.
- The safety profile of topical PDE4 inhibitors in this population appears comparable to vehicle treatment.
- PDE4 inhibitors are a promising and potentially safe therapeutic option for managing pediatric atopic dermatitis.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
315
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
315
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
368
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
368
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
664
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
664
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
439
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
439
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
62
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
62
01:29Drug Dosing: Infants and Children
705
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
705